{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:53:21Z","timestamp":1768348401910,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/s11882-005-0078-9","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T01:24:15Z","timestamp":1180833855000},"page":"333-338","source":"Crossref","is-referenced-by-count":28,"title":["Ocular cicatricial pemphigoid: Manifestations and management"],"prefix":"10.1007","volume":"5","author":[{"given":"John H.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"78_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","volume":"138","author":"LS Chan","year":"2002","unstructured":"Chan LS, Ahmed AR, Anhalt GJ, et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002, 138:370\u2013379. This is the first international consensus outlining recommendations regarding the definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators for MMP and OCP.","journal-title":"Arch Dermatol"},{"key":"78_CR2","first-page":"527","volume":"84","author":"CS Foster","year":"1986","unstructured":"Foster CS: Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986, 84:527\u2013663.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"78_CR3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0161-6420(81)35069-6","volume":"88","author":"BJ Mondino","year":"1981","unstructured":"Mondino BJ, Brown SI: Ocular cicatricial pemphigoid. Ophthalmology 1981, 88:95\u2013100.","journal-title":"Ophthalmology"},{"key":"78_CR4","first-page":"65","volume":"160","author":"H Bettelheim","year":"1972","unstructured":"Bettelheim H, Kraft D, Zehetbauer G: Uber den sogenanneten Augenpemphigus (pemphigus ocularis; pemphigus conjunctivae). Klin Monatsbl Augenheilkd 1972, 160:65\u201375.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"78_CR5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/archopht.1934.00830110053006","volume":"11","author":"RC Smith","year":"1934","unstructured":"Smith RC, Myers EA, Lamb HD: Ocular and oral pemphigus: report of case with anatomic findings in eyeball. Arch Ophthalmol 1934, 11:635\u2013640.","journal-title":"Arch Ophthalmol"},{"key":"78_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00003226-199105000-00001","volume":"10","author":"J Tauber","year":"1991","unstructured":"Tauber J, Sainz de la Maza M, Foster CS: Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991, 10:185\u2013195.","journal-title":"Cornea"},{"key":"78_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","volume":"111","author":"JE Thorne","year":"2004","unstructured":"Thorne JE, Anhalt GJ, Jabs DA: Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 2004, 111:45\u201352.","journal-title":"Ophthalmology"},{"key":"78_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.104.5.467","volume":"104","author":"KM Hardy","year":"1971","unstructured":"Hardy KM, Perry HO, Pingree GC, Kirby TJ Jr: Benign mucous membrane pemphigoid. Arch Dermatol 1971, 104:467\u2013475.","journal-title":"Arch Dermatol"},{"key":"78_CR9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/eye.1994.45","volume":"8","author":"MJ Elder","year":"1994","unstructured":"Elder MJ, Lightman S: The immunological features and pathophysiology of ocular cicatricial pemphigoid. Eye 1994, 8:196\u2013199.","journal-title":"Eye"},{"key":"78_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ophtha.2003.07.010","volume":"111","author":"P McCluskey","year":"2004","unstructured":"McCluskey P, Chang JH, Singh R, Wakefield D: Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004, 111:796\u2013801. This study reports for the first time that low-dose oral methotrexate monotherapy is both highly efficacious and well tolerated as the firstline systemic agent in the treatment of OCP and drug-induced OCP.","journal-title":"Ophthalmology"},{"key":"78_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00003226-199209000-00015","volume":"11","author":"J Tauber","year":"1992","unstructured":"Tauber J, Jabbur N, Foster CS: Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea 1992, 11:446\u2013451.","journal-title":"Cornea"},{"key":"78_CR12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0161-6420(79)35486-0","volume":"86","author":"BJ Mondino","year":"1979","unstructured":"Mondino BJ, Brown SI, Lempert S, Jenkins MS: The acute manifestations of ocular cicatricial pemphigoid: diagnosis and treatment. Ophthalmology 1979, 86:543\u2013555.","journal-title":"Ophthalmology"},{"key":"78_CR13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjo.80.4.292","volume":"80","author":"MJ Elder","year":"1996","unstructured":"Elder MJ, Bernauer W, Leonard J, Dart JK: Progression of disease in ocular cicatricial pemphigoid. Br J Ophthalmol 1996, 80:292\u2013296.","journal-title":"Br J Ophthalmol"},{"key":"78_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0161-6420(01)00863-6","volume":"109","author":"E Miserocchi","year":"2002","unstructured":"Miserocchi E, Baltatzis S, Roque MR, et al.: The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002, 109:111\u2013118. This is the first major study to assess the treatment-related side effects of systemic immunomodulatory therapy in OCP. Dapsone was the drug with the greatest number of complications, whereas methotrexate was the most benign chemotherapeutic agent.","journal-title":"Ophthalmology"},{"key":"78_CR15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1442-9071.1992.tb00751.x","volume":"20","author":"IC Francis","year":"1992","unstructured":"Francis IC, McCluskey PJ, Wakefield D, Branley MG: Medial canthal keratinisation (MCK): a diagnostic sign of ocular cicatricial pemphigoid. Aust NZ J Ophthalmol 1992, 20:350\u2013351.","journal-title":"Aust NZ J Ophthalmol"},{"key":"78_CR16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0161-6420(95)30896-2","volume":"102","author":"WJ Power","year":"1995","unstructured":"Power WJ, Neves RA, Rodriguez A, et al.: Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthalmology 1995, 102:1158\u20131163.","journal-title":"Ophthalmology"},{"key":"78_CR17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9394(14)77908-5","volume":"96","author":"BJ Mondino","year":"1983","unstructured":"Mondino BJ, Brown SI: Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983, 96:453\u2013459.","journal-title":"Am J Ophthalmol"},{"key":"78_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bjo.79.3.264","volume":"79","author":"MJ Elder","year":"1995","unstructured":"Elder MJ, Lightman S, Dart JK: Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 1995, 79:264\u2013246.","journal-title":"Br J Ophthalmol"},{"key":"78_CR19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0161-6420(82)34791-0","volume":"89","author":"CS Foster","year":"1982","unstructured":"Foster CS, Wilson LA, Ekins MB: Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982, 89:340\u2013353.","journal-title":"Ophthalmology"},{"key":"78_CR20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.76.6.332","volume":"76","author":"AI Fern","year":"1992","unstructured":"Fern AI, Jay JL, Young H, MacKie R: Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol 1992, 76:332\u2013335.","journal-title":"Br J Ophthalmol"},{"key":"78_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJM198503283121303","volume":"312","author":"ME Weinblatt","year":"1985","unstructured":"Weinblatt ME, Coblyn JS, Fox DA, et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818\u2013822.","journal-title":"N Engl J Med"},{"key":"78_CR22","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0161-6420(92)31790-7","volume":"99","author":"SS Shah","year":"1992","unstructured":"Shah SS, Lowder CY, Schmitt MA, et al.: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992, 99:1419\u20131423.","journal-title":"Ophthalmology"},{"key":"78_CR23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0161-6420(01)00657-1","volume":"108","author":"S Doan","year":"2001","unstructured":"Doan S, Lerouic JF, Robin H, et al.: Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology 2001, 108:1565\u20131568.","journal-title":"Ophthalmology"},{"key":"78_CR24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjo.80.6.549","volume":"80","author":"MJ Elder","year":"1996","unstructured":"Elder MJ, Leonard J, Dart JK: Sulphapyridine: a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996, 80:549\u2013552.","journal-title":"Br J Ophthalmol"},{"key":"78_CR25","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","volume":"106","author":"CS Foster","year":"1999","unstructured":"Foster CS, Ahmed AR: Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999, 106:2136\u20132143. The first preliminary, uncontrolled study reporting that intravenous immunoglobulin therapy can be a safe and effective therapy for otherwise treatment-refractory OCP.","journal-title":"Ophthalmology"},{"key":"78_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","volume":"111","author":"E Letko","year":"2004","unstructured":"Letko E, Miserocchi E, Daoud YJ, et al.: A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004, 111:303\u2013310. This study reports that intravenous immunoglobulin therapy was more effective in arresting the progression of OCP when compared with conventional immunosuppressive therapy.","journal-title":"Clin Immunol"},{"key":"78_CR27","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","volume":"111","author":"N Sami","year":"2004","unstructured":"Sami N, Letko E, Androudi S, et al.: Intravenous immunoglobulin therapy in patients with ocular cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004, 111:1380\u20131382.","journal-title":"Ophthalmology"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-005-0078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-005-0078-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-005-0078-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-005-0078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:30:45Z","timestamp":1652614245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-005-0078-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s11882-005-0078-9","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}